⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SMMT News
Summit Therapeutics Inc. Common Stock
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
businesswire.com
SMMT
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
prnewswire.com
SMMT
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
businesswire.com
SMMT
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
prnewswire.com
SMMT
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway ® in Combination with Ivonescimab Across Multiple Tumor Types
businesswire.com
AZN
SMMT
High-Stakes October has these Biotechs Entering Crucial Stretch
globenewswire.com
IOVA
NTHI
SMMT
AZN
Form 8-K
sec.gov
SMMT
Form 8-K
sec.gov
SMMT
Form 8-K
sec.gov
SMMT
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
businesswire.com
SMMT